Discovery Pipeline

Speaking at BIO 2026, Infinimune's Dr Wyatt McDonnell explains how the company’s human-derived antibody platform enables multi-objective optimization that AI alone and transgenic models cannot replicate.

The deal, announced at BIO 2026, carries total potential value exceeding $2.5 billion and will use Insilico's Pharma.AI platform to drive target-to-candidate discovery across neuroinflammatory, neurodegenerative, and rare neurological indications.

Takeda will use Boltz biomolecular AI models to support structure prediction, affinity estimation, and molecular design in preclinical research.

Basel’s innovation campus is expanding with new research institutes, laboratories, and collaborative infrastructure for life sciences growth.

Biohub has released an open-source AI protein design model aimed at early drug discovery, with initial testing in cancer and immune targets.

Artificial intelligence delivers meaningful value in drug development only when it is grounded in real-world constraints and tightly integrated into expert-led workflows, rather than treated as a standalone, model-first solution.

Isomorphic Labs’ $2.1 billion financing will support expansion of its AI-driven drug discovery platform and advancement of therapeutic candidates toward clinical development.

The opening plenary session at this year’s AAPS National Biotechnology Conference will spotlight AI and NAMs as tools that advance predictive toxicology and human-relevant models to improve drug safety and translational research.

Boehringer Ingelheim is expanding its investment in AI for R&D in London to advance computational approaches to disease biology and drug discovery in biopharmaceuticals.

Expanding natural chemical space may improve AI drug discovery by providing biologically relevant data to generate more clinically impactful therapeutics, says Guillaume Vandenesch, CEO and co-founder of Generare, in this exclusive interview.

Novo Nordisk intends to apply advanced AI to analyze complex data, improve target identification, and accelerate development of therapies for chronic diseases

Through collaboration, Imagene AI and Daiichi Sankyo will apply multimodal AI to improve biomarker discovery with the goals of advancing precision oncology and enhancing clinical trial success rates.

The funding will support expansion of evolution-derived molecule datasets, enabling discovery of novel bioactive compounds and improving AI model performance in drug development.

In a new collaboration, Tempus and Daiichi Sankyo will apply AI-driven biomarker discovery to improve ADC patient selection with the aim of advancing precision strategies in competitive oncology pipelines.

With Sanofi as one of its backers, Earendil Labs is set to advance its AI-native biologics platform to scale antibody discovery, accelerate IND filings, and expand partnerships in autoimmune and oncology research.

The launch of Excalipoint Therapeutics brings to the table multi-specific T-cell engager platforms that aim to overcome tumor microenvironment barriers and expand efficacy into solid tumors and immunology indications.

Johnson & Johnson reports encouraging Phase 1b data for its bispecific antibody pasritamig in combination with docetaxel in metastatic castration-resistant prostate cancer, showing strong PSA responses and manageable safety

Under the collaboration, Merck and Mayo Clinic will integrate multimodal clinical and genomic datasets with AI models to enhance target biology insights and translational decision-making.

AI, biomarkers, and novel oncology modalities are driving evolution in biopharma pipelines, according to Nmblr CEO Janice MacLennan.

AdvanCell and 48Hour Discovery align peptide discovery with a Lead-212 infrastructure to build a durable targeted alpha therapy pipeline aimed at oncology markets.

Agentic AI enables closed-loop, autonomous drug discovery workflows that accelerate biopharma R&D, improve efficiency, and reshape innovation.

The company’s major long-term capital commitment highlights how global drugmakers are anchoring future innovation, advanced modalities, and supply resilience within China’s life sciences ecosystem.

Next-gen antibody R&D is shifting to multifunctional modalities driven by manufacturing scale and regulatory acceleration.

The new GSK–Oxford BioTherapeutics partnership capitalizes on proteomics-driven oncology target discovery for advancing antibody therapeutics development.

RxCelerate and Constructive Bio will combine programmable biology with integrated discovery tools to speed engineered biologics for hard-to-treat diseases.